Weekly Analysts’ Ratings Changes for WAVE Life Sciences (WVE)

A number of firms have modified their ratings and price targets on shares of WAVE Life Sciences (NASDAQ: WVE) recently:

• 10/28/2026 – WAVE Life Sciences had its “outperform” rating reaffirmed by Oppenheimer.
• 10/27/2026 – WAVE Life Sciences was given a new $10.00 price target by Leerink Partners.
• 10/16/2026 – WAVE Life Sciences is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – WAVE Life Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – WAVE Life Sciences is now covered by UBS Group. They set a “buy” rating and a $11.00 price target on the stock.
• 10/14/2026 – WAVE Life Sciences was upgraded by UBS Group to “strong-buy”.
• 10/2/2026 – WAVE Life Sciences was given a new $13.00 price target by Wedbush.
• 10/2/2026 – WAVE Life Sciences had its “buy” rating reaffirmed by HC Wainwright.
• 10/1/2026 – WAVE Life Sciences is now covered by LADENBURG THALM/SH SH. They set a “buy” rating and a $10.00 price target on the stock.
• 9/23/2026 – WAVE Life Sciences is now covered by JPMorgan Chase & Co.. They set a “neutral” rating on the stock.

Insider Transactions at WAVE Life Sciences

In related news, Director Heidi Wagner sold 7,000 shares of WAVE Life Sciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $6.01, for a total transaction of $42,070.00. Following the transaction, the director owned 44,930 shares of the company’s stock, valued at $270,029.30. This trade represents a 13.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Adrian Rawcliffe sold 12,700 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total transaction of $67,183.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 23,564 shares of company stock valued at $132,476. 24.34% of the stock is currently owned by company insiders.

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.